昆仑万维科技股份有限公司投资者关系活动记录表 编号：2025-003 | 投资者关系活动 | □特定对象调研 □分析师会议 | | --- | --- | | 类别 | □媒体采访 √业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 来自东吴证券、华泰证券、国泰海通、中航证券、国联民生、 | | 人员姓名 | 山西证券、中邮证券、中信证券、中信建投、中泰证券、国元 | | | 证券、西南证券、华鑫证券、信达证券、甬兴证券、野村证券、 | | | 汇丰前海、大和日华、银华基金、鹏华基金、易米基金、南方 | | | 基金、京管泰富、弘毅基金、集元资产、南土资产、磐厚动量、 | | | 聚鸣投资、健顺投资、睿扬投资、宏道投资、致顺投资、弘章 | | | 基金等 58 位机构投资者 | | 时间 | 2025 年 8 月 25 日 16:00-17:00 | | 地点 | 电话会议 | | 上市公司接待人 | 昆仑万维 董事长兼 CEO 方汉先生 | | 员姓名 | 昆仑万维 战略副总裁 牟竹云先生 方总回顾公司 20 ...

证券代码： 300465 证券简称：高伟达 | 投资者关系活动 | 特定对象调研 □ □ | 分析师会议 | | --- | --- | --- | | 类别 | 媒体采访 □ □ | 业绩说明会 | | | 新闻发布会 □ □ | 路演活动 | | | □ 现场参观 | | | | √ 其他 （投资者交流活动） | | | 参与单位名称及 | 上海肇万资产管理有限公司：崔磊； | | | 人员姓名 | 中庚基金管理有限公司：王震； | | | | 长江证券股份有限公司（自营）：肖知雨； | | | | 上海人寿保险股份有限公司：魏 | 蔓； | | | 新华基金：王永明； | | | | 泰信基金管理有限公司：吴秉韬； | | | | 乾璐投资：吴晓； | | | | 建信基金管理有限责任公司：蒋严泽 | | | 时间 | 年 月 日 (周三) 2025 8 27 | 20:00-20:43 | | 地点 | 线上会议 | | | 上市公司接待人 员姓名 | 董秘、财务总监高源 | | | 投资者关系活动 | 1、公司 2025 年上半年业务发展和业绩情况如何？ 。 | | | | 2025 年半年度营业收 ...

Financial Performance - In the first half of 2025, the company's revenue reached 3,010.46 million CNY, with a net profit attributable to shareholders of 42.9 million CNY, and a net cash flow from operating activities of 1,788.09 million CNY, achieving a year-on-year growth of 364.33% [2][4] - The overall gross margin for the first half of 2025 increased to 39.93%, up by 5.32% compared to the same period last year [3][7] Sales Channels and Market Strategy - The company maintained over 60% sales from commercial chains, approximately 20% from medical channels, and around 20% from online and other channels, with overall sales performance remaining stable compared to the previous year [4] - The company is leveraging e-commerce platforms like JD and Tmall to enhance market share and develop potential markets [4] Product Development and Innovation - The company is focusing on the secondary development of four unique products, including the Ren Shen Gu Ben Wan and Fu Fang Huang Qi Jian Pi Oral Liquid, aiming to enhance their market competitiveness through technological upgrades [6] - Major products with strong sales in the first half of 2025 include Liu Wei Di Huang Wan, Er Chen Wan, and An Gong Niu Huang Wan, with plans to continue promoting these key products [5] International Expansion - The company has exported products to 32 countries and regions, including the USA, Canada, and Australia, and has achieved significant international certifications, including TGA and PIC/S [8] - Future plans include increasing international market share through brand collaboration and channel sharing [8] Cost Management and Future Planning - The decrease in sales expenses is attributed to a decline in revenue and effective cost control measures implemented by the company [8] - The company is actively developing its "14th Five-Year Plan," focusing on marketing breakthroughs, brand building, and innovation in research and development [8]

证券代码：002432 证券简称：九安医疗 天津九安医疗电子股份有限公司 投资者关系活动记录表 | | √特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 √业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 线上参与单位 | 网上业绩说明会：通过网络远程方式参加公司"2025 年半年度网上业 | | 名称及人员姓 | 绩说明会"的广大投资者。 | | 名 | 特定对象调研：具体参会机构清单，详见后附"特定调研对象清单"。 | | 时间 | 网上业绩说明会：2025 年 8 月 27 日 15：00-16：00 | | | 特定对象调研：2025 年 8 月 27 日 16：15-17：15 | | 方式 | 网上业绩说明会：网络远程文字方式 | | | 特定对象调研：电话会议方式 | | 上市公司接待 | 董事长、总经理：刘毅 先生 | | | 董事、副总经理：王湧 先生 | | | 董事、副总经理：丛明 先生 | | 人员姓名 | 独立董事：孙卫军 先生 | | | 董事会秘书：邬彤 先生 | | | 财务经理（代行 ...

Financial Performance - In the first half of 2025, the company achieved operating revenue of CNY 1.869 billion, a decrease of 12.56% year-on-year [3] - Operating profit was CNY 347 million, down 15.22% year-on-year [3] - Net profit attributable to shareholders was CNY 308 million, a decline of 9.26% year-on-year [3] - Earnings per share were CNY 0.3116, down 9.26% year-on-year [3] - The gross profit margin was 63.16%, an increase from 54.8% in the previous year [5] Revenue Breakdown - Revenue from formulations was CNY 1.127 billion, a decrease of 7.2% year-on-year [3] - Revenue from raw materials and intermediates was CNY 730 million, down 20% year-on-year [3] - Sales of gynecological and family planning formulations were CNY 207 million, down 11% year-on-year [4] - Sales of respiratory formulations increased by 13% to CNY 446 million [4] - Sales of generic drugs decreased by 23% to CNY 230 million, primarily due to regional procurement impacts [4] R&D and Innovation - R&D expenses for the first half of 2025 were CNY 126 million, with a R&D expense ratio of 6.7% [7] - The company is transitioning from traditional generics to high-barrier formulations, facing challenges but aiming for innovation [7] - New product approvals include several formulations and a focus on high-value sterile raw materials [8] Shareholder Returns - Total dividends distributed over the first five years since listing amounted to CNY 1.187 billion, with CNY 890 million in the last three years [6] - For the first half of 2025, the company plans to distribute CNY 98.92 million in cash dividends [6] Market Outlook - The raw material market is experiencing a downward price trend, impacting revenue and profits [8] - The company aims to enhance competitiveness by developing high-value raw materials and expanding hormone categories [8] Product Development - The company is actively pursuing new product registrations, including a long-acting analgesic injection and a new inhalation spray [9][11] - Sales of certain products, such as the progestin injection, have seen significant growth, with a 30% increase in sales for the first half of 2025 [13] Strategic Focus - The company is focused on building a capable sales team to support the commercialization of innovative drugs [18] - The impact of national procurement policies on product sales is being monitored, with a gradual reduction in overall impact as more products are included in procurement [19] - Future plans include expanding export capabilities and ensuring compliance with international registration requirements [20]

Group 1: Financial Performance - In the first half of 2025, the company achieved a net profit of approximately 35 billion CNY, with pig farming contributing about 51 billion CNY in profit and chicken farming incurring a loss of about 12 billion CNY [2][3] - The company's net profit for Q1 was 21 billion CNY, while Q2 net profit was approximately 15 billion CNY, with pig farming profit in Q2 around 26 billion CNY [2][3] Group 2: Production and Sales - From January to July 2025, the company sold a total of 21.1 million pigs, including 19.26 million in fresh and live pigs and 1.83 million piglets; chicken sales reached 709 million, with 123 million being fresh sales [4] - The company maintained a pig market release rate of approximately 93% in June, with a feed-to-meat ratio of 2.55 [6] Group 3: Cost Management - The comprehensive cost of pig farming decreased to 6.2 CNY per jin, a year-on-year reduction of about 1.2 CNY per jin, with market factors affecting approximately 40% and non-market factors about 60% [6] - The average comprehensive cost of pig farming across regions was 6.2 CNY per jin, with a variance of less than 0.2 CNY per jin among three pig farming divisions [12] Group 4: Debt and Investment - As of June 2025, the company's debt-to-asset ratio decreased to 50.6%, down 2.8% from the end of the previous year, with a target to reduce it to around 45% [9][22] - The company planned a fixed asset investment of approximately 5 billion CNY for 2025, with 2 billion CNY already invested in the first half, including 1.4 billion CNY in pig farming [23][24] Group 5: Strategic Initiatives - The company is restructuring its poultry division into three business units to enhance management efficiency and promote healthy competition [10] - A new brand strategy was introduced, adding "Wens Food" and "Wens Ingredients" to better segment the business [10]

Financial Performance - The company achieved a total revenue of 870 million CNY, with a net profit attributable to shareholders of 83.16 million CNY, and a net cash flow from operating activities of 167 million CNY, resulting in a gross profit margin of 24.42% [3] - As of June 30, 2025, total assets amounted to 2.534 billion CNY, and net assets attributable to shareholders were 1.598 billion CNY [3] - In Q2 2025, revenue reached 450 million CNY, with a net profit of 42.98 million CNY, both showing a quarter-on-quarter growth of 7% [3] Automotive Electronics Business - The automotive electronics segment generated revenue of 455 million CNY, accounting for 52.32% of total revenue, but experienced a year-on-year decline of 21.70% due to delivery setbacks from traditional automotive electronics and Panasonic clients [3] - The company is actively responding to challenges, with new clients like Nidec and Hitachi Astemo beginning to ramp up production [3] Smart Terminal Business - The smart terminal segment reported revenue of 229 million CNY, representing 26.26% of total revenue, with a year-on-year growth of 6.34% [3] - Products in this category are primarily used in smart set-top boxes, network gateways, and smart meters, with ongoing collaborations with major clients [3] Server Business Developments - The server business has secured multiple new clients, expanding into personal supercomputer server components and power supply structures [4] - A strategic cooperation agreement was signed with Green Cloud Map for liquid cooling server products, focusing on production and technology development [4] Consumer Electronics Business - Revenue from consumer electronics reached 70.03 million CNY, making up 8.04% of total revenue, with a year-on-year growth of 14.25% [4] - The focus in this area remains on extending existing products rather than pursuing new strategic initiatives [4] Production Capacity and Expansion - The company has established six production bases globally, with the Thailand facility having its groundbreaking ceremony on March 9, 2025, and the Suzhou expansion project reaching its topping-off ceremony on April 9, 2025 [4] - Efforts are ongoing to enhance local management in Vietnam and Indonesia to ensure sustainable growth over the next two years [4] Future Business Focus - The company aims to leverage its core manufacturing capabilities to expand into various sectors, particularly in robotics and computing servers [4]

Group 1: Product Development and Innovation - The company focuses on three main product directions: harmonic reducers, joint modules, and cycloidal reducers [2][3] - In the harmonic reducer sector, the company is developing lightweight products using aluminum-steel composites and special PEEK materials, receiving positive market feedback, especially in humanoid robotics [2][3] - The joint module is being enhanced through self-developed technologies to improve torque-to-weight ratio and energy efficiency, with energy consumption reduced by 50% compared to previous models [3][4] Group 2: Competitive Advantages - The company has established strong partnerships with key players like Weichuang Electric for technology training and production, enhancing overall capabilities [4] - There is significant room for innovation in the structure and material selection of harmonic reducers, giving integrated manufacturers an edge in optimizing joint module business [4][5] - The integration of resources from Keda Li, Taiwan Mengli, and Taiwan Mengying has created a global service network, facilitating customer cooperation [5] Group 3: Market Dynamics and Challenges - The sample testing cycle for customers typically lasts at least 1-2 months, with ongoing adjustments needed due to rapid advancements in humanoid robotics technology [6] - The production lines for cycloidal reducers can be shared with harmonic reducers, utilizing wire cutting technology to enhance precision and rigidity [7] - The company's reducers are designed to be lightweight, energy-efficient, and high in transmission efficiency, with aluminum-steel reducers being 30%-60% lighter than standard products while maintaining strength and improving heat dissipation [7]

Financial Performance - In the first half of 2025, the company achieved operating revenue of 8.34 billion CNY, a year-on-year increase of 9.93% [2] - The net profit attributable to shareholders was 69.81 million CNY, a decline of 70.03% compared to the same period last year [2] - The net profit after deducting non-recurring gains and losses was 88.49 million CNY, down 74.70% year-on-year [2] - As of June 30, 2025, total assets reached 9.25 billion CNY, an increase of 18.08% year-on-year, while net assets grew by 8.23% to 1.81 billion CNY [2] Product Sales and Market Position - The company sold 879.86 tons of photovoltaic conductive paste, a decrease of 22.28% year-on-year [2] - Sales of N-type TOPCon battery conductive paste reached 834.74 tons, accounting for 94.87% of total sales, maintaining a leading position in the industry [2] Technological Development and Future Plans - The company plans to enhance product technology research and market expansion to solidify its leading position in the photovoltaic battery conductive paste sector [3] - The high copper paste solution for TOPCon batteries has achieved mass production, with a clear timeline for large-scale production set for the second half of the year [4] - The silver nitrate project is expected to begin trial production in Q4 2025, which will enhance supply chain stability and reduce raw material costs [5] Cost Efficiency and Product Innovation - The high copper paste solution significantly reduces silver consumption by over 50% compared to standard processes [7] - The processing fees for TOPCon silver paste remain stable, while HJT and TBC paste processing fees are higher, indicating potential for improved profitability with the growth of new battery technologies [6] Semiconductor and Electronic Materials - The company’s sales revenue from storage chips reached 189 million CNY in the first half of 2025, with expectations for continued growth in the second half due to industry demand [9]

Financial Performance - The company achieved a revenue of 7.92 billion yuan in the first half of 2025, representing a year-on-year growth of 45.52% [4] - Revenue growth by product category: - Pet snacks: +64.63% - Pet leashes: +6.91% - Pet food: +55.39% - Pet toys: +47.93% - Other revenues: +103.04% [4] - Domestic revenue increased by 136.77%, while overseas revenue grew by 31.44% [4] - Net profit attributable to shareholders was 7,416.36 million yuan, a slight increase of 0.37% compared to the previous year [4] - Gross margin for the first half of 2025 was 21.51%, down from 22.44% year-on-year [4] Sales and Marketing Strategy - Sales expenses for the first half of 2025 were 3,368.39 million yuan, an increase of 97.13% year-on-year, driven by a focus on expanding domestic market presence [5] - The company is emphasizing three major self-owned brands: Pikapoo, Halewi, and Legend Elf, with increased investment in domestic sales [5] Production and Supply Chain - The company operates two factories in Cambodia, both of which are currently at full production capacity [7] - The Cambodian factories are expected to increase capacity significantly with new constructions projected to be operational by mid-2026 [7] Impact of Tariffs - The company’s orders for the U.S. market are primarily produced in Cambodia, where tariffs have been adjusted to 19% this year. However, this has not significantly impacted operations [6] Market Position and Growth - The company is expanding its customer base from channel clients to brand clients, which is increasing order volumes [9] - Continuous innovation and product development are key to meeting diverse customer needs and maintaining growth in overseas markets [9]